{"id":51842,"date":"2025-12-23T16:20:40","date_gmt":"2025-12-23T08:20:40","guid":{"rendered":"https:\/\/flcube.com\/?p=51842"},"modified":"2025-12-23T16:20:41","modified_gmt":"2025-12-23T08:20:41","slug":"alphamab-jskn003-adc-fda-breakthrough-therapy-targets-ovarian-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=51842","title":{"rendered":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer"},"content":{"rendered":"\n<p><strong>Alphamab Oncology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9966:HKG\">HKG: 9966<\/a>) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), <strong>JSKN003<\/strong>, has been granted <strong>Breakthrough Therapy Designation (BTD)<\/strong> by the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-product-profile\">Regulatory Milestone &amp; Product Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Alphamab Oncology (HKG: 9966)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>JSKN003<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>FDA Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced\/metastatic platinum\u2011resistant recurrent ovarian\/peritoneal\/fallopian tube cancer with HER2 expression (IHC 1+, 2+, or 3+)<\/td><\/tr><tr><td><strong>Prior Therapy<\/strong><\/td><td>Patients must have received prior bevacizumab<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>HER2\u2011targeting biparatopic ADC<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First biparatopic HER2 ADC with DAR 4; binds two distinct HER2 epitopes<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-technical-differentiation\">Mechanism of Action &amp; Technical Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biparatopic Design<\/strong>: Binds to two distinct epitopes of HER2 on tumor cells, enhancing internalization<\/li>\n\n\n\n<li><strong>ADC Payload<\/strong>: Releases <strong>topoisomerase I inhibitor<\/strong> upon internalization<\/li>\n\n\n\n<li><strong>DAR Optimization<\/strong>: <strong>Drug-to-antibody ratio (DAR) of 4<\/strong> achieved through site\u2011specific conjugation to Fc glycans of anbenitamab<\/li>\n\n\n\n<li><strong>Manufacturing<\/strong>: Stable, homogeneous ADC profile for consistent therapeutic effect<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-licensing-partnership-amp-regional-rights\">Licensing Partnership &amp; Regional Rights<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Agreement Element<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Counterparty<\/strong><\/td><td>JMT\u2011Bio Technology (wholly\u2011owned subsidiary of CSPC Pharmaceutical Group, 1093.HK)<\/td><\/tr><tr><td><strong>Deal Date<\/strong><\/td><td>September\u202f2024<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China (excludes Hong Kong, Macau, Taiwan)<\/td><\/tr><tr><td><strong>Rights<\/strong><\/td><td>Exclusive license for oncology indications<\/td><\/tr><tr><td><strong>Marketing Authorization Holder<\/strong><\/td><td>JMT\u2011Bio serves as sole MAH for oncology indications in Mainland China<\/td><\/tr><tr><td><strong>Manufacturing Rights<\/strong><\/td><td>Alphamab Oncology retains exclusive manufacturing rights<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-outlook\">Market Context &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PROC Market<\/strong>: <strong>50,000\u201170,000<\/strong> patients in US annually; <strong>HER2\u2011expressing subset<\/strong> represents significant unmet need<\/li>\n\n\n\n<li><strong>ADC Landscape<\/strong>: HER2 ADCs dominate breast cancer; expansion into ovarian cancer offers <strong>$1\u20112 billion<\/strong> market opportunity<\/li>\n\n\n\n<li><strong>Breakthrough Advantage<\/strong>: BTD accelerates FDA review timeline from 10\u201112 months to 6\u20118 months<\/li>\n\n\n\n<li><strong>Global Development<\/strong>: US BTD strengthens China regulatory position; pivotal trial initiation planned for <strong>Q2\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Analysts project <strong>$500\u2011800 million<\/strong> peak global sales if approved across HER2\u2011expressing solid tumors<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding JSKN003 development timelines, clinical outcomes, and partnership execution. Actual results may differ due to clinical, regulatory, and competitive uncertainties.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":51843,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,187,16,83,854],"class_list":["post-51842","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-alphamab-oncology","tag-cancer","tag-her2","tag-hkg-9966"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=51842\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer\" \/>\n<meta property=\"og:description\" content=\"Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=51842\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-23T08:20:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-23T08:20:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer\",\"datePublished\":\"2025-12-23T08:20:40+00:00\",\"dateModified\":\"2025-12-23T08:20:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842\"},\"wordCount\":340,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2308.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Alphamab Oncology\",\"Cancer\",\"HER2\",\"HKG: 9966\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51842#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=51842\",\"name\":\"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2308.webp\",\"datePublished\":\"2025-12-23T08:20:40+00:00\",\"dateModified\":\"2025-12-23T08:20:41+00:00\",\"description\":\"Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=51842\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2308.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/2308.webp\",\"width\":1080,\"height\":608,\"caption\":\"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=51842#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=51842","og_locale":"en_US","og_type":"article","og_title":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer","og_description":"Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.","og_url":"https:\/\/flcube.com\/?p=51842","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-23T08:20:40+00:00","article_modified_time":"2025-12-23T08:20:41+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=51842#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=51842"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer","datePublished":"2025-12-23T08:20:40+00:00","dateModified":"2025-12-23T08:20:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=51842"},"wordCount":340,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=51842#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp","keywords":["ADC \/ XDC","Alphamab Oncology","Cancer","HER2","HKG: 9966"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=51842#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=51842","url":"https:\/\/flcube.com\/?p=51842","name":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=51842#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=51842#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp","datePublished":"2025-12-23T08:20:40+00:00","dateModified":"2025-12-23T08:20:41+00:00","description":"Alphamab Oncology (HKG: 9966) announced that its independently developed HER2\u2011targeting biparatopic antibody\u2011drug conjugate (ADC), JSKN003, has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum\u2011resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer (PROC) with HER2 expression.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=51842#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=51842"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=51842#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp","width":1080,"height":608,"caption":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=51842#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Alphamab JSKN003 ADC FDA Breakthrough Therapy Targets Ovarian Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/2308.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51842","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=51842"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51842\/revisions"}],"predecessor-version":[{"id":51844,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/51842\/revisions\/51844"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/51843"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=51842"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=51842"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=51842"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}